Optimization of conventional therapy in patients with IBD (original) (raw)

• Colombel, J. F. et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N. Engl. J. Med. 362, 1383–1395 (2010).
  Article CAS PubMed Google Scholar
• Pannacionne, R. et al. Infliximab, azathioprine, or infliximab + azathioprine for treatment of moderate to severe ulcerative colitis: The UC Success Trial. Gastroenterology 140 (Suppl. 1), S134 (2011).
  Article Google Scholar
• Gisbert, J. P. & Panes, J. Loss of response and requirement of infliximab dose intensification in Crohn's disease: a review. Am. J. Gastroenterol. 104, 760–767 (2009).
  Article CAS PubMed Google Scholar
• Louis, E. et al. Infliximab discontinuation in Crohn's disease patients in stable remission on combined therapy with immunosuppressors: interim analysis of a prospective cohort study. Gut 57, A66 (2008).
  Google Scholar
• Infliximab (review) and adalimumab for the treatment of Crohn's disease. NICE technology appraisal guidance 187. National Institute for Clinical Excellence [online], (2010).
• Irving, P. M., Gearry, B., Sparrow, M. P. & Gibson, P. R. Review article: appropriate use of corticosteroids in Crohn's disease. Aliment. Pharmacol. Ther. 26, 313–329 (2007).
  Article CAS PubMed Google Scholar
• Gearry, R. B. & Irving, P. M. Biologics for inflammatory bowel diseases in the Asia-Pacific: can we afford to use them, can we afford not to? J. Gastroenterol. Hepatol. 24, 1160–1162 (2009).
  Article PubMed Google Scholar
• Ford, A. C., Khan, K. J., Talley, N. J. & Moayyedi, P. 5-aminosalicylates prevent relapse of Crohn's disease after surgically induced remission: systematic review and meta-analysis. Am. J. Gastroenterol. 106, 413–420 (2011).
  Article CAS PubMed Google Scholar
• Hanauer, S. et al. Mesalamine capsules for treatment of active ulcerative colitis: results of a controlled trial. Pentasa Study Group. Am. J. Gastroenterol. 88, 1188–1197 (1993).
  CAS PubMed Google Scholar
• Kane, S. V. Systematic review: adherence issues in the treatment of ulcerative colitis. Aliment. Pharmacol. Ther. 23, 577–585 (2006).
  Article CAS PubMed Google Scholar
• Kane, S. V., Cohen, R. D., Aikens, J. E. & Hanauer, S. B. Prevalence of nonadherence with maintenance mesalamine in quiescent ulcerative colitis. Am. J. Gastroenterol. 96, 2929–2933 (2001).
  Article CAS PubMed Google Scholar
• Cerveny, P. et al. Non-adherence in inflammatory bowel disease: results of factor analysis. Inflamm. Bowel Dis. 13, 1244–1249 (2007).
  Article PubMed Google Scholar
• Kane, S., Huso, D., Aikens, J. & Hanauer, S. Medication nonadherence and the outcomes of patients with quiescent ulcerative colitis. Am. J. Med. 114, 39–43 (2003).
  Article PubMed Google Scholar
• Sandborn, W. J. et al. MMX Multi Matrix System mesalazine for the induction of remission in patients with mild-to-moderate ulcerative colitis: a combined analysis of two randomized, double-blind, placebo-controlled trials. Aliment. Pharmacol. Ther. 26, 205–215 (2007).
  Article CAS PubMed Google Scholar
• Kamm, M. A. et al. Randomised trial of once- or twice-daily MMX mesalazine for maintenance of remission in ulcerative colitis. Gut 57, 893–902 (2008).
  Article CAS PubMed Google Scholar
• Rubin, D. T. et al. Impact of ulcerative colitis from patients' and physicians' perspectives: results from the UC:NORMAL survey. Inflamm. Bowel Dis. 15, 581–588 (2009).
  Article PubMed Google Scholar
• Dignass, A. U. et al. Mesalamine once daily is more effective than twice daily in patients with quiescent ulcerative colitis. Clin. Gastroenterol. Hepatol. 7, 762–769 (2009).
  Article CAS PubMed Google Scholar
• Hanauer, S. B. et al. Delayed-release oral mesalamine 4.8mg/day (800mg tablets) compared with 2.4g/day (400mg tablets) for the treatment of mildly to moderately active ulcerative colitis: the ASCEND I trial. Can. J. Gastroenterol. 21, 827–834 (2007).
  Article CAS PubMed PubMed Central Google Scholar
• Hanauer, S. B. et al. Delayed-release oral mesalamine at 4.8g/day (800mg tablet) for the treatment of moderately active ulcerative colitis: the ASCEND II trial. Am. J. Gastroenterol. 100, 2478–2485 (2005).
  Article CAS PubMed Google Scholar
• Sandborn, W. J. et al. Delayed-release oral mesalamine 4.8g/day (800mg tablet) is effective for patients with moderately active ulcerative colitis. Gastroenterology 137, 1934–1943 (2009).
  Article CAS PubMed Google Scholar
• Lichtenstein, G. R., Kamm, M. A., Sandborn, W. J., Lynes, A. & Joseph, R. E. MMX mesalazine for the induction of remission in mild-to-moderately active ulcerative colitis:efficacy and tolerability in specific patient subpopulations. Aliment. Pharmacol. Ther. 27, 1094–1102 (2008).
  Article CAS PubMed Google Scholar
• Kruis, W. et al. Randomised clinical trial: a comparative dose-finding study of three arms of dual release mesalazine for maintaining remission in ulcerative colitis. Aliment. Pharmacol. Ther. 33, 313–322 (2011).
  Article CAS PubMed Google Scholar
• Hussain, F. N., Ajjan, R. A. & Riley, S. A. Dose loading with delayed-release mesalazine: a study of tissue drug concentrations and standard pharmacokinetic parameters. Br. J. Clin. Pharmacol. 49, 323–330 (2000).
  Article CAS PubMed PubMed Central Google Scholar
• Katz, S. & Pasquale, M. Daily dosing of delayed release mesalamine prior to immunosuppressive use [Abstract 1199]. Presented at the 74th American College of Gastroenterology Annual Scientific Meeting San Diego, California: 2009.
• Safdi, M. et al. A double-blind comparison of oral versus rectal mesalamine versus combination therapy in the treatment of distal ulcerative colitis. Am. J. Gastroenterol. 92, 1867–1871 (1997).
  CAS PubMed Google Scholar
• Marteau, P. et al. Combined oral and enema treatment with Pentasa (mesalazine) is superior to oral therapy alone in patients with extensive mild/moderate active ulcerative colitis: a randomised, double-blind, placebo controlled study. Gut 54, 960–965 (2005).
  Article CAS PubMed PubMed Central Google Scholar
• Hanauer, S. et al. Long-term use of mesalazine (Rowasa) suppositories in remission maintenance of ulcerative proctitis. Am. J. Gastroenterol. 95, 1749–1754 (2000).
  Article CAS PubMed Google Scholar
• d'Albasio, G. et al. Combined therapy with 5-aminosalicylic acid tablets and enemas for maintaining remission in ulcerative colitis: a randomized double-blind study. Am. J. Gastroenterol. 92, 1143–1147 (1997).
  CAS PubMed Google Scholar
• van Bodegraven, A. A., Boer, R. O., Lourens, J., Tuynman, H. A. & Sindram, J. W. Distribution of mesalazine enemas in active and quiescent ulcerative colitis. Aliment. Pharmacol. Ther. 10, 327–332 (1996).
  Article CAS PubMed Google Scholar
• Kamm, M. A. et al. Effect of extended MMX mesalamine therapy for acute, mild-to-moderate ulcerative colitis. Inflamm. Bowel Dis. 15, 1–8 (2009).
  Article PubMed Google Scholar
• Orchard, T. R., van der Geest, S. A. & Travis, S. P. Randomised clinical trial: early assessment after 2 weeks of high-dose mesalazine for moderately active ulcerative colitis—new light on a familiar question. Aliment. Pharmacol. Ther. 33, 1028–1035 (2011).
  Article CAS PubMed Google Scholar
• Sandborn, W. J. et al. MMX mesalamine (SPD476), a novel, high-strength 5-ASA formulation induces remission of active, mild-to-moderate ulcerative colitis in subjects that are switched from low-dose oral 5-ASA therapy or are 5-ASA naive: an analysis of pooled data from two phase III studies. Digestive Diseases Week Los Angeles, CA: 2006. Poster T1139.
  Google Scholar
• Pruitt, R. et al. Balsalazide as alternative therapy to mesalamine dose-escalation for acute, mild to moderate ulcerative colitis. Gastroenterology 122, A299 (2002).
  Article CAS Google Scholar
• Sandborn, W. J., Fazio, V. W., Feagan, B. G. & Hanauer, S. B. AGA technical review on perianal Crohn's disease. Gastroenterology 125, 1508–1530 (2003).
  Article PubMed Google Scholar
• Van Assche, G. et al. The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: special situations. J. Crohns Colitis 4, 63–101 (2010).
  Article PubMed Google Scholar
• Thia, K. T. et al. Ciprofloxacin or metronidazole for the treatment of perianal fistulas in patients with Crohn's disease: a randomized, double-blind, placebo-controlled pilot study. Inflamm. Bowel Dis. 15, 17–24 (2009).
  Article PubMed Google Scholar
• Blichfeldt, P., Blomhoff, J. P., Myhre, E. & Gjone, E. Metronidazole in Crohn's disease. A double blind cross-over clinical trial. Gastroenterology 13, 123–127 (1978).
  CAS Google Scholar
• Steinhart, A. H. et al. Combined budesonide and antibiotic therapy for active Crohn's disease: a randomized controlled trial. Gastroenterology 123, 33–40 (2002).
  Article CAS PubMed Google Scholar
• Brandt, L. J. et al. Metronidazole therapy for perianal Crohn's disease: a follow-up study. Gastroenterology 83, 383–387 (1982).
  CAS PubMed Google Scholar
• Arnold, G. L., Beaves, M. R., Pryjdun, V. O. & Mook, W. J. Preliminary study of ciprofloxacin in active Crohn's disease. Inflamm. Bowel Dis. 8, 10–15 (2002).
  Article PubMed Google Scholar
• Prantera, C. et al. Antibiotic treatment of Crohn's disease: results of a multicentre, double blind, randomized, placebo-controlled trial with rifaximin. Aliment. Pharmacol. Ther. 23, 1117–1125 (2006).
  Article CAS PubMed Google Scholar
• Rutgeerts, P. et al. Ornidazole for prophylaxis of postoperative Crohn's disease recurrence: a randomized, double-blind, placebo-controlled trial. Gastroenterology 128, 856–861 (2005).
  Article CAS PubMed Google Scholar
• Rutgeerts, P. et al. Controlled trial of metronidazole treatment for prevention of Crohn's recurrence after ileal resection. Gastroenterology 108, 1617–1621 (1995).
  Article CAS PubMed Google Scholar
• D'Haens, G. R. et al. Therapy of metronidazole with azathioprine to prevent postoperative recurrence of Crohn's disease: a randomized, double-blind, placebo-controlled randomized trial. Gastroenterology 135, 1123–1129 (2008).
  Article CAS PubMed Google Scholar
• Madden, M. V., McIntyre, A. S. & Nicholls, R. J. Double-blind crossover trial of metronidazole versus placebo in chronic unremitting pouchitis. Dig. Dis. Sci. 39, 1193–1196 (1994).
  Article CAS PubMed Google Scholar
• Shen, B. et al. A randomized clinical trial of ciprofloxacin and metronidazole to treat acute pouchitis. Inflamm. Bowel Dis. 7, 301–305 (2001).
  Article CAS PubMed Google Scholar
• Hurst, R. D., Molinari, M., Chung, T. P., Rubin, M. & Michelassi, F. Prospective study of the incidence, timing and treatment of pouchitis in 104 consecutive patients after restorative proctocolectomy. Arch. Surg. 131, 497–500 (1996).
  Article CAS PubMed Google Scholar
• Gionchetti, P. et al. Antibiotic combination therapy in patients with chronic, treatment-resistant pouchitis. Aliment. Pharmacol. Ther. 13, 713–718 (1999).
  Article CAS PubMed Google Scholar
• Mimura, T. et al. Four-week open-label trial of metronidazole and ciprofloxacin for the treatment of recurrent or refractory pouchitis. Aliment. Pharmacol. Ther. 16, 909–917 (2002).
  Article CAS PubMed Google Scholar
• Nygaard, K. et al. Topical metronidazole treatment in pouchitis. Scand. J. Gastroenterol. 29, 462–467 (1994).
  Article CAS PubMed Google Scholar
• Isaacs, K. L. et al. Rifaximin for the treatment of active pouchitis: a randomized, double-blind, placebo-controlled pilot study. Inflamm. Bowel Dis. 13, 1250–1255 (2007).
  Article PubMed Google Scholar
• Baron, J. H., Connell, A. M., Kanaghinis, T. G., Lennard-Jones, J. E. & Avery Jones, F. Outpatient treatment of ulcerative colitis: comparison between three doses of oral prednisone. Br. Med. J. 2, 1713–1718 (1962).
  Article Google Scholar
• Brignola, C. et al. Steroid treatment in active Crohn's disease: a comparison between two regimens of different duration. Aliment. Pharmacol. Ther. 8, 465–468 (1994).
  Article CAS PubMed Google Scholar
• Dignass, A. et al. The second European evidence-based consensus on the diagnosis and management of Crohn's disease: current management. J. Crohn's Colitis 4, 28–62 (2010).
  Article CAS Google Scholar
• Lichtenstein, G. R., Abreu, M. T., Cohen, R. & Tremaine, W. American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. Gastroenterology 130, 940–987 (2006).
  Article CAS PubMed Google Scholar
• Seow, C. H., Benchimol, E. I., Griffiths, A. M., Otley, A. R. & Steinhart, A. H. Budesonide for induction of remission in Crohn's disease. Cochrane Database Systematic Reviews, Issue 3, Art. No.: CD000296. doi:10.1002/14651858.CD000296.pub3 (2008).
• Sandborn, W. J. et al. Budesonide MMX 9 mg for the induction of remission of mild-to-moderate ulcerative colitis (UC): data from a multicenter, randomized, double-blind placebo-controlled study in North America and India. Gastroenterology 140 (Suppl. 1), S124 (2011).
  Google Scholar
• Sandborn, W. J. et al. Budesonide MMX 9 mg for induction of remission of mild-to-moderate ulcerative colitis (UC): data from a multicenter, randomized, double-blind placebo-controlled study in Europe, Russia, Israel and Australia. Gastroenterology 140 (Suppl. 1), S65 (2011).
  Google Scholar
• Campierei, M. et al. Oral beclometasone dipropionate in the treatment of extensive and left-sided active ulcerative colitis: a multicentre randomised study. Aliment. Pharmacol. Ther. 17, 1471–1480 (2003).
  Article Google Scholar
• Manguso, F. & Balzano, A. Meta-analysis: the efficacy of rectal beclomethasone dipropionate vs. 5-aminosalicylic acid in mild to moderate distal ulcerative colitis. Aliment. Pharmacol. Ther. 26, 21–29 (2007).
  Article CAS PubMed Google Scholar
• McIntyre, P. B., Marin, F. A., Berghouse, L., English, J. & Lennard-Jones, J. E. Therapeutic benefits from a poorly absorbed prednisolone enema in distal colitis. Gut 26, 822–824 (1985).
  Article CAS PubMed PubMed Central Google Scholar
• Rhodes, J. M. et al. Clinical trial: oral prednisolone metasulfobenzoate (Predocol) vs oral prednisolone for active ulcerative colitis. Aliment. Pharmacol. Ther. 27, 228–240 (2008).
  Article CAS PubMed Google Scholar
• Bossa, F. et al. Erythrocyte-mediated delivery of dexamethasone in patients with mild-to-moderate ulcerative colitis, refractory to mesalamine: a randomized, controlled study. Am. J. Gastroenterol. 103, 2509–2516 (2008).
  Article CAS PubMed Google Scholar
• Prefontaine, E., MacDonald, J. K. & Sutherland, L. R. Azathioprine or 6-mercaptopurine for induction of remission in Crohn's disease. Cochrane Database of Systematic Reviews, Art. No.: CD000545. doi:10/1002/14651858.CD000545.pub3 (2010).
• Ardizzone, S. et al. Randomised controlled trial of azathioprine and 5-aminosalicylic acid for treatment of steroid dependent ulcerative colitis. Gut 55, 47–53 (2006).
  CAS PubMed PubMed Central Google Scholar
• Pearson, D. C., May, G. R., Fick, G. H. & Sutherland, L. R. Azathioprine and 6-mercaptopurine in Crohn's disease. A meta-analysis. Ann. Intern. Med. 122, 132–142 (1995).
  Article Google Scholar
• Reinisch, W. et al. Azathioprine versus mesalazine for prevention of postoperative clinical recurrence in patients with Crohn's disease with endoscopic recurrence: efficacy and safety results of a randomised, double-blind, double-dummy, multicentre trial. Gut 59, 752–759 (2010).
  Article CAS PubMed Google Scholar
• Punati, J. et al. Effect of early immunomodulator use in moderate to severe pediatric Crohn disease. Inflamm. Bowel Dis. 14, 949–954 (2008).
  Article PubMed Google Scholar
• Gisbert, J. P. et al. Comparative effectiveness of azathioprine in Crohn's disease and ulcerative colitis: a prospective, long-term, follow-up study of 394 patients. Aliment. Pharmacol. Ther. 28, 228–238 (2008).
  Article CAS PubMed Google Scholar
• D'Haens, G., Geboes, K. & Rutgeerts, P. Endoscopic and histologic healing of Crohn's (ileo-) colitis with azathioprine. Gastrointest. Endosc. 50, 667–671 (1999).
  Article CAS PubMed Google Scholar
• Mantzaris, G. J. et al. Azathioprine is superior to budesonide in achieving and maintaining mucosal healing and histologic remission in steroid-dependent Crohn's disease. Inflamm. Bowel Dis. 15, 375–382 (2009).
  Article PubMed Google Scholar
• Ramadas, A. V., Gunesh, S., Thomas, G. A., Williams, G. T. & Hawthorne, A. B. Natural history of Crohn's disease in a population-based cohort from Cardiff (1986–2003): a study of changes in medical treatment and surgical resection rates. Gut 59, 1200–1206 (2010).
  Article CAS PubMed Google Scholar
• Prefontaine, E., Sutherland, L. R., Macdonald, J. K. & Cepiou, M. Azathioprine or 6-mercaptopurine for maintenance of remission in Crohn's disease. Cochrane Database Systematic Reviews, Issue 1. Art. No.: CD000067. doi:10.1002/14651858.CD000067.pub2 (2009).
• Timmer, A., McDonald, J. W. & Macdonald, J. K. Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis. Cochrane Database Systematic Reviews, Issue 1. Art. No.: CD000478. doi:10.1002/14651858.CD000478.pub2 (2007).
• Gardiner, S. J., Gearry, R. B., Begg, E. J., Zhang, M. & Barclay, M. L. Thiopurine dose in intermediate and normal metabolizers of thiopurine methyltransferase may differ three-fold. Clin. Gastroenterol. Hepatol. 6, 654–660 (2008).
  Article CAS PubMed Google Scholar
• Hindorf, U. et al. Pharmacogenetics during standardised initiation of thiopurine treatment in inflammatory bowel disease. Gut 55, 1423–1431 (2006).
  Article CAS PubMed PubMed Central Google Scholar
• Osterman, M. T., Kundu, R., Lichtenstein, G. R. & Lewis, J. D. Association of 6-thioguanine nucleotide levels and inflammatory bowel disease activity: a meta-analysis. Gastroenterology 130, 1047–1053 (2006).
  Article CAS PubMed Google Scholar
• Dubinsky, M. C. et al. Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology 118, 705–713 (2000).
  Article CAS PubMed Google Scholar
• Hindorf, U., Johansson, M., Eriksson, A., Kvifors, E. & Almer, S. H. Mercaptopurine treatment should be considered in azathioprine intolerant patients with inflammatory bowel disease. Aliment. Pharmacol. Ther. 29, 654–661 (2009).
  Article CAS PubMed Google Scholar
• Jharap, B. et al. Thiopurine therapy in inflammatory bowel disease patients: analyses of two 8-year intercept cohorts. Inflamm. Bowel Dis. 16, 1541–1549 (2010).
  Article CAS PubMed Google Scholar
• Gearry, R. B. et al. Thiopurine methyltransferase and 6-thioguanine nucleotide measurement: early experience of use in clinical practice. Intern. Med. J. 35, 580–585 (2005).
  Article CAS PubMed Google Scholar
• Roblin, X. et al. 6-tioguanine monitoring in steroid-dependent patients with inflammatory bowel disease receiving azathioprine. Aliment. Pharmacol. Ther. 21, 829–839 (2005).
  Article CAS PubMed Google Scholar
• Roblin, X. et al. A 6-TGN level threshold of 400pmol/8x108 erythrocytes is a predictive factor of AZA resistance in IBD patients without clinical remission. Gastroenterology 128 (Suppl. 2), A12 (2005).
  Google Scholar
• Sparrow, M. P., Hande, S. A., Friedman, S., Cao, D. & Hanauer, S. B. Effect of allopurinol on clinical outcomes in inflammatory bowel disease nonresponders to azathioprine or 6-mercaptopurine. Clin. Gastroenterol. Hepatol. 5, 209–214 (2007).
  Article CAS PubMed Google Scholar
• Ansari, A. et al. Long-term outcome of using allopurinol co-therapy as a strategy for overcoming thiopurine hepatotoxicity in treating inflammatory bowel disease. Aliment. Pharmacol. Ther. 28, 734–741 (2008).
  Article CAS PubMed Google Scholar
• Leung, Y., Sparrow, M. P., Schwartz, M. & Hanauer, S. B. Long term efficacy and safety of allopurinol and azathioprine or 6-mercaptopurine in patients with inflammatory bowel disease. J. Crohns Colitis 3, 162–167 (2009).
  Article PubMed Google Scholar
• Haines, M. L. et al. Clinical usefulness of therapeutic drug monitoring of thiopurines in patients with adequately controlled inflammatory bowel disease. Inflamm. Bowel Dis. 17, 1301–1307 (2011).
  Article PubMed Google Scholar
• Alfadhli, A. A., McDonald, J. W. & Feagan, B. G. Methotrexate for the induction of remission in refractory Crohn's disease. Cochrane Database Systematic Reviews, Issue 1. Art. No.: CD003459. doi:10.1002/14651858.CD003459.pub2 (2005).
• Patel, V., Macdonald, J. K., McDonald, J. W. & Chande, N. Methotrexate for maintenance of remission in Crohn's disease. Cochrane Database Systematic Reviews, Issue 4. Art. No.: CD006884. doi:10.1002/14651858.CD006884.pub2 (2009).
• Oren, R. et al. Methotrexate in chronic active ulcerative colitis: a double-blind, randomized, Israeli multicentre trial. Gastroenterology 110, 1416–1421 (1996).
  Article CAS PubMed Google Scholar
• Cummings, J. R. et al. Oral methotrexate in ulcerative colitis. Aliment. Pharmacol. Ther. 21, 385–389 (2005).
  Article CAS PubMed Google Scholar
• Paoluzi, O. A. et al. Azathioprine or methotrexate in the treatment of patients with steroid-dependent or steroid-resistant ulcerative colitis: results of an open-label study on efficacy and tolerability in inducing and maintaining remission. Aliment. Pharmacol. Ther. 16, 1751–1759 (2002).
  Article CAS PubMed Google Scholar
• Nathan, D. M., Iser, J. H. & Gibson, P. R. A single center experience of methotrexate in the treatment of Crohn's disease and ulcerative colitis: a case for subcutaneous administration. J. Gastroenterol. Hepatol. 6, 954–958 (2007).
  Google Scholar
• Feagan, B. G. et al. A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease. North American Crohn's Study Group Investigators. N. Engl. J. Med. 342, 1627–1632 (2000).
  Article CAS PubMed Google Scholar
• Fraser, A. G., Morton, D., McGovern, D., Travis, S. & Jewell, D. P. The efficacy of methotrexate for maintaining remission in inflammatory bowel disease. Aliment. Pharmacol. Ther. 16, 693–697 (2002).
  Article CAS PubMed Google Scholar
• Kurnki, D. et al. Bioavailability of oral vs subcutaneous low-dose methotrexate in patients with Crohn's disease. Aliment. Pharmacol. Ther. 18, 57–63 (2003).
  Article Google Scholar
• Teresi, M. E., Crom, W. R., Choi, K. E., Mirro, J. & Evans, W. E. Methotrexate bioavailability after oral and intramuscular administration in children. J. Pediatr. 110, 788–792 (1987).
  Article CAS PubMed Google Scholar
• Hoekstra, M. et al. Splitting high-dose oral methotrexate improves bioavailability: a pharmacokinetic study in patients with rheumatoid arthritis. J. Rheumatol. 33, 481–485 (2006).
  CAS PubMed Google Scholar
• Chong, R. Y., Hanauer, S. B. & Cohen, R. D. Efficacy of parenteral methotrexate in refractory Crohn's disease. Aliment. Pharmacol. Ther. 15, 35–44 (2001).
  Article CAS PubMed Google Scholar
• Wahed, M. et al. Efficacy of methotrexate in Crohn's disease and ulcerative colitis patients unresponsive or intolerant to azathioprine / mercaptopurine. Aliment. Pharmacol. Ther. 30, 614–620 (2009).
  Article CAS PubMed Google Scholar
• Stamp, L. et al. The use of low dose methotrexate in rheumatoid arthritis—are we entering a new era of therapeutic drug monitoring and pharmacogenomics? Biomed. Pharmacother. 60, 678–687 (2006).
  Article CAS PubMed Google Scholar
• Egan, L. J. et al. A randomized dose-response and pharmacokinetic study of methotrexate for refractory inflammatory Crohn's disease and ulcerative colitis. Aliment. Pharmacol. Ther. 13, 1597–1604 (1999).
  Article CAS PubMed Google Scholar
• Weinshilboum, R. M. & Sladek, S. L. Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am. J. Human Genet. 32, 651–662 (1980).
  CAS Google Scholar
• Ganiere-Monteil, C. et al. Phenotype and genotype for thiopurine methyltransferase activity in the French Caucasian population: impact of age. Eur. J. Clin. Pharmacol. 60, 89–96 (2004).
  Article CAS PubMed Google Scholar
• Rossi, A. M., Bianchi, M., Guarnieri, C., Barale, R. & Pacific, G. M. Genotype-phenotype correlation for thiopurine S-methyltransferase in healthy Italian subjects. Eur. J. Clin. Pharmacol. 57, 51–54 (2001).
  Article CAS PubMed Google Scholar
• Kamm, M. A. et al. Once-daily, high-concentration MMX mesalamine in active ulcerative colitis. Gastroenterology 132, 1–66 (2007).
  Article CAS Google Scholar
• Lichtenstein, G. R. et al. Effect of once- or twice-daily MMX mesalamine (SPD476) for the induction of remission of mild to moderately active ulcerative colitis. Clin. Gastroenterol. Hepatol. 5, 95–102 (2007).
  Article CAS PubMed Google Scholar
• Kruis, W. et al. Once daily versus three times daily mesalazine granules in active ulcerative colitis: a double-blind, double-dummy, randomised, non-inferiority trial. Gut 58, 223–240 (2009).
  Article CAS Google Scholar
• Kamm, M. A. et al. Randomised trial of once- or twice-daily MMX mesalazine for maintenance of remission in ulcerative colitis. Gut 57, 893–902 (2008).
  Article CAS PubMed Google Scholar
• Hawthorne, A. B. et al. Once daily Asacol in maintenance therapy for ulcerative colitis: a one-year single-blind randomised trial. Gut 60 (Suppl. 1), A37–A38 (2011).
  Article Google Scholar
• Gearry, R. B. & Barclay, M. L. Azathioprine and 6-mercaptopurine pharmacogenetics and metabolite monitoring in inflammatory bowel disease. J. Gastroenterol. Hepatol. 20, 1149–1157 (2005).
  Article CAS PubMed Google Scholar